The effects of an orally administered cholinergic agonist on REM sleep in major depression
Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine...
Gespeichert in:
| Veröffentlicht in: | Biological psychiatry (1969) 2002-03, Vol.51 (6), p.457-462 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 462 |
|---|---|
| container_issue | 6 |
| container_start_page | 457 |
| container_title | Biological psychiatry (1969) |
| container_volume | 51 |
| creator | PERLIS, Michael L SMITH, Michael T ORFF, Henry J ANDREWS, Patrick J GILLIN, J. Christian GILES, Donna E |
| description | Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8).
All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM.
The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p =.04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3).
These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders. |
| doi_str_mv | 10.1016/S0006-3223(01)01287-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71550036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71550036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-dc287d2343992689174b8b36116160a88f45d4cbccdb75d91a843a35de1bcefb3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlZ_gpKLoofVTLKfRyn1AyqC1ouXkE1m28jupibbQ_-92w_saZjheWeGh5BLYPfAIH34ZIylkeBc3DK4Y8DzLOJHZAh5JiIeM35Mhv_IgJyF8NO3GedwSgYABe8DxZB8zxZIsapQd4G6iqqWOq_qek2VaWxrQ4ceDdULV9sW_dxqquZuM6eupR-TNxpqxCW1LW3Uj_PU4NJjCNa15-SkUnXAi30dka-nyWz8Ek3fn1_Hj9NIC5F0kdH9J4aLWBQFT_MCsrjMS5ECpJAyledVnJhYl1qbMktMASqPhRKJQSg1VqUYkZvd3qV3vysMnWxs0FjXqkW3CjKDJGFMpD2Y7EDtXQgeK7n0tlF-LYHJjVS5lSo3xiQDuZUqeZ-72h9YlQ2aQ2pvsQeu94AKWtWVV6224cCJdKOeiT9jon8c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71550036</pqid></control><display><type>article</type><title>The effects of an orally administered cholinergic agonist on REM sleep in major depression</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>PERLIS, Michael L ; SMITH, Michael T ; ORFF, Henry J ; ANDREWS, Patrick J ; GILLIN, J. Christian ; GILES, Donna E</creator><creatorcontrib>PERLIS, Michael L ; SMITH, Michael T ; ORFF, Henry J ; ANDREWS, Patrick J ; GILLIN, J. Christian ; GILES, Donna E</creatorcontrib><description>Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8).
All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM.
The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p =.04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3).
These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/S0006-3223(01)01287-2</identifier><identifier>PMID: 11922879</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Administration, Oral ; Adult ; Adult and adolescent clinical studies ; Biological and medical sciences ; Cholinergic Agents - administration & dosage ; Cholinesterase Inhibitors - administration & dosage ; Depression ; Depressive Disorder, Major - diagnosis ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - genetics ; Donepezil ; Female ; Humans ; Indans - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Mood disorders ; Piperidines - administration & dosage ; Polysomnography ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Reaction Time - drug effects ; Single-Blind Method ; Sleep, REM - drug effects ; Sleep, REM - genetics</subject><ispartof>Biological psychiatry (1969), 2002-03, Vol.51 (6), p.457-462</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-dc287d2343992689174b8b36116160a88f45d4cbccdb75d91a843a35de1bcefb3</citedby><cites>FETCH-LOGICAL-c335t-dc287d2343992689174b8b36116160a88f45d4cbccdb75d91a843a35de1bcefb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13600070$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11922879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PERLIS, Michael L</creatorcontrib><creatorcontrib>SMITH, Michael T</creatorcontrib><creatorcontrib>ORFF, Henry J</creatorcontrib><creatorcontrib>ANDREWS, Patrick J</creatorcontrib><creatorcontrib>GILLIN, J. Christian</creatorcontrib><creatorcontrib>GILES, Donna E</creatorcontrib><title>The effects of an orally administered cholinergic agonist on REM sleep in major depression</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8).
All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM.
The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p =.04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3).
These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Biological and medical sciences</subject><subject>Cholinergic Agents - administration & dosage</subject><subject>Cholinesterase Inhibitors - administration & dosage</subject><subject>Depression</subject><subject>Depressive Disorder, Major - diagnosis</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - genetics</subject><subject>Donepezil</subject><subject>Female</subject><subject>Humans</subject><subject>Indans - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Piperidines - administration & dosage</subject><subject>Polysomnography</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Reaction Time - drug effects</subject><subject>Single-Blind Method</subject><subject>Sleep, REM - drug effects</subject><subject>Sleep, REM - genetics</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotlZ_gpKLoofVTLKfRyn1AyqC1ouXkE1m28jupibbQ_-92w_saZjheWeGh5BLYPfAIH34ZIylkeBc3DK4Y8DzLOJHZAh5JiIeM35Mhv_IgJyF8NO3GedwSgYABe8DxZB8zxZIsapQd4G6iqqWOq_qek2VaWxrQ4ceDdULV9sW_dxqquZuM6eupR-TNxpqxCW1LW3Uj_PU4NJjCNa15-SkUnXAi30dka-nyWz8Ek3fn1_Hj9NIC5F0kdH9J4aLWBQFT_MCsrjMS5ECpJAyledVnJhYl1qbMktMASqPhRKJQSg1VqUYkZvd3qV3vysMnWxs0FjXqkW3CjKDJGFMpD2Y7EDtXQgeK7n0tlF-LYHJjVS5lSo3xiQDuZUqeZ-72h9YlQ2aQ2pvsQeu94AKWtWVV6224cCJdKOeiT9jon8c</recordid><startdate>20020315</startdate><enddate>20020315</enddate><creator>PERLIS, Michael L</creator><creator>SMITH, Michael T</creator><creator>ORFF, Henry J</creator><creator>ANDREWS, Patrick J</creator><creator>GILLIN, J. Christian</creator><creator>GILES, Donna E</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020315</creationdate><title>The effects of an orally administered cholinergic agonist on REM sleep in major depression</title><author>PERLIS, Michael L ; SMITH, Michael T ; ORFF, Henry J ; ANDREWS, Patrick J ; GILLIN, J. Christian ; GILES, Donna E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-dc287d2343992689174b8b36116160a88f45d4cbccdb75d91a843a35de1bcefb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Biological and medical sciences</topic><topic>Cholinergic Agents - administration & dosage</topic><topic>Cholinesterase Inhibitors - administration & dosage</topic><topic>Depression</topic><topic>Depressive Disorder, Major - diagnosis</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - genetics</topic><topic>Donepezil</topic><topic>Female</topic><topic>Humans</topic><topic>Indans - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Piperidines - administration & dosage</topic><topic>Polysomnography</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Reaction Time - drug effects</topic><topic>Single-Blind Method</topic><topic>Sleep, REM - drug effects</topic><topic>Sleep, REM - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PERLIS, Michael L</creatorcontrib><creatorcontrib>SMITH, Michael T</creatorcontrib><creatorcontrib>ORFF, Henry J</creatorcontrib><creatorcontrib>ANDREWS, Patrick J</creatorcontrib><creatorcontrib>GILLIN, J. Christian</creatorcontrib><creatorcontrib>GILES, Donna E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PERLIS, Michael L</au><au>SMITH, Michael T</au><au>ORFF, Henry J</au><au>ANDREWS, Patrick J</au><au>GILLIN, J. Christian</au><au>GILES, Donna E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of an orally administered cholinergic agonist on REM sleep in major depression</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>2002-03-15</date><risdate>2002</risdate><volume>51</volume><issue>6</issue><spage>457</spage><epage>462</epage><pages>457-462</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8).
All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM.
The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p =.04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3).
These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.</abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>11922879</pmid><doi>10.1016/S0006-3223(01)01287-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-3223 |
| ispartof | Biological psychiatry (1969), 2002-03, Vol.51 (6), p.457-462 |
| issn | 0006-3223 1873-2402 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71550036 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Adult Adult and adolescent clinical studies Biological and medical sciences Cholinergic Agents - administration & dosage Cholinesterase Inhibitors - administration & dosage Depression Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Donepezil Female Humans Indans - administration & dosage Male Medical sciences Middle Aged Mood disorders Piperidines - administration & dosage Polysomnography Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Reaction Time - drug effects Single-Blind Method Sleep, REM - drug effects Sleep, REM - genetics |
| title | The effects of an orally administered cholinergic agonist on REM sleep in major depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A01%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20an%20orally%20administered%20cholinergic%20agonist%20on%20REM%20sleep%20in%20major%20depression&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=PERLIS,%20Michael%20L&rft.date=2002-03-15&rft.volume=51&rft.issue=6&rft.spage=457&rft.epage=462&rft.pages=457-462&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/S0006-3223(01)01287-2&rft_dat=%3Cproquest_cross%3E71550036%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71550036&rft_id=info:pmid/11922879&rfr_iscdi=true |